WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Clinical Pharmacology of Antiparasitic Drugs and Antiparasitic-Drug Interactions

[1]Mushtarii Baktierova, [2]Abhishek Raja, [3]Dar Junaid Ahmad, [4]Mohsin Reyaz, [5]Manickavel Suriya Nithish

[1-4]Osh State University, Kyrgyzstan

ABSTRACT

Parasitic infections, caused by protozoa, helminths, and ectoparasites, are a predominant cause of morbidity and mortality worldwide, with heavy focus in tropical and subtropical nations. Effective treatment depends on antiparasitic drug therapy, consisting of a diverse group of chemical classes that target a particular stage of parasite life. The clinical pharmacology involves a complete understanding of their mechanisms of action, pharmacokinetics, pharmacodynamics, toxicity, and drug interactions. Complications of resistance development, host-specificity issues, and regional factors complicate treatment strategy. This article is a comprehensive description of the pharmacological properties of clinically employed antiparasitic drugs, highlighting molecular mechanisms, pharmacokinetic profiles, side effects, drug interactions, patterns of resistance, and therapeutic concerns. The review also includes new strategies, including new drug discovery, combination therapy, and pharmacogenomics, and is a guide for clinicians, pharmacologists, and medical students to achieve optimal parasite control.

1. Introduction

1.1 Epidemiology and Global Burden

Parasitic disease is endemic in most of the world and infects more than 3 billion people globally. Main parasite groups are:

1. Protozoa: Plasmodium species (malaria), Entamoeba histolytica (amebiasis), Giardia lamblia, Trichomonas vaginalis, Leishmania spp., and Trypanosoma spp.

2. Helminths: nematodes (roundworms, filaria), cestodes (tapeworms), and trematodes (flukes).

3. Ectoparasites: lice, scabies mites, and ticks.

Malaria alone causes over 400,000 deaths annually, primarily among children less than five years of age resident in the sub-Saharan Africa region. Helminthic infection, including soil-transmitted helminths and schistosomiasis, produces chronic disease, undernutrition, and impaired intellectual performance. The global burden suggests the need for effective antiparasitic drug treatment in combination with public health interventions.

1.2 Historical Background

Historically, antiparasitic drug discovery has taken centuries:

•**Quinine**, extracted from bark of Cinchona trees, was the first effective antimalarial since the 17th century.

•**Artemisinin,** derived from Artemisia annua, is a modern plant-based antimalarial with quick action against multidrug-resistant Plasmodium falciparum.

•**Helminthic** therapy evolved with the development of benzimidazoles in the 1970s and ivermectin in the 1980s, revolutionizing filarial disease control.

The pharmacotherapy history reflects continued issues of resistance, safety, and availability.

1.3 Rationale for Studying Clinical Pharmacology

Knowledge of clinical pharmacology is important in:

•Selecting agents based on species of **parasite, life stage, and patient.**

•Modifying **dose, route, and duration** to achieve maximal efficacy and avoid toxicity.

•Anticipating and avoiding **drug interactions** and side effects.

•Preventing **resistance** by combination therapy and rational therapy.

2. Classification of Antiparasitic Drugs

Antiparasitic drugs can be classified by target parasite groups, mechanism, or chemical structure. Table 1 depicts major drug classes.

Class	Examples	Target Parasites	Primary Mechanism
Antimalarials	Chloroquine, Quinine, Artemisinin, Mefloquine, Primaquine, Atovaquone-Proguanil	*Plasmodium* spp.	Disruption of heme detoxification, free radical generation, folate inhibition
Antiprotozoals	Metronidazole, Tinidazole, Nitazoxanide, Pentamidine, Paromomycin	*Entamoeba*, *Giardia*, *Trichomonas*, *Leishmania*, *Trypanosoma*	DNA damage, protein synthesis inhibition, energy metabolism disruption
Antihelminthics	Albendazole, Mebendazole, Ivermectin, Praziquantel, Pyrantel	Nematodes, cestodes, trematodes	Microtubule inhibition, neuromuscular blockade, calcium homeostasis disruption
Antifilarials	Diethylcarbamazine, Ivermectin, Albendazole	Filarial nematodes	Membrane alteration, paralysis, micro filarial clearance
Antischistosomal	Praziquantel, Oxamniquine	*Schistosoma* spp.	Calcium-mediated paralysis, DNA damage
Ectoparasiticides	Permethrin, Lindane, Topical Ivermectin	Lice, scabies mites	Sodium channel blockade, GABA receptor inhibition

3. Mechanisms of Action

Antiparasitic drugs exploit unique parasite biochemistry and physiology to become selectively toxic.

3.1 Antimalarials

•**Chloroquine:** Inhibits heme polymerization to hemozoin within the parasite food vacuole → toxic heme accumulation.

•**Quinine:** Disrupts heme detoxification as well as nucleic acid synthesis.

•**Artemisinin derivatives:** Activated by iron in heme → yield reactive oxygen species → destroy parasite membranes and proteins.

•**Primaquine:** Interferes with mitochondrial electron transport in hepatic hypnozoites, preventing relapse.

•**Mefloquine:** Destabilizes parasite membranes and heme metabolism.

•**Atovaquone-Proguanil:** Atovaquone inhibits mitochondrial electron transport; proguanil inhibits dihydrofolate reductase → synergistic antimalarial action.

3.2 Antiprotozoal Drugs

•**Metronidazole/Tinidazole:** Reduced in anaerobic protozoa → production of free radicals → DNA strand breakage.

•**Nitazoxanide:** Intercepts pyruvate: ferredoxin oxidoreductase, inhibiting anaerobic energy metabolism.

•**Paromomycin:** Binds 30S ribosomal RNA → inhibits protein synthesis.

•**Pentamidine:** Inhibits DNA, RNA, and polyamine synthesis; binds mitochondrial DNA.

3.3 Antihelminthics

•**Benzimidazoles:** Binds β-tubulin → destabilizes microtubules → inhibited glucose uptake → death of parasites.

•Increased glutamate-gated chloride channel activity → hyperpolarization → paralysis.

•Augment Ca^{2+} permeability → muscle contraction and detachment.

•Depolarizing neuromuscular blockade → expulsion via peristalsis.

•Diethylcarbamazine:Surface membranes of microfilariae are modified → increased phagocytosis.

3.4 Ectoparasiticides

•**Permethrin:** Inhibition of sodium channel repolarization → arthropod paralysis.

•**Lindane:** GABA receptor antagonism → neuronal hyperexcitation → death.

•**Topical Ivermectin:** Mite Cl^- channel hyperpolarization.

4. Pharmacokinetics and Pharmacodynamics

4.1 Absorption

•Most antiparasitic drugs are orally bioavailable; different absorptions.

•Faty meals enhance albendazole uptake; antacids inhibit chloroquine uptake.

4.2 Distribution

•Free drug levels are influenced by protein binding: chloroquine (~50–60% bound to protein), quinine (~70%).

•Tissue accumulation in liver, spleen, lungs, and red cells (especially antimalarials).

4.3 Metabolism

•Primarily hepatic via CYP450 enzymes.

•CYP3A4 and CYP2C19 are notable enzymes; induction/inhibition affects plasma levels.

4.4 Excretion

•**Renal:** metronidazole, quinine.

•**Biliary:** albendazole metabolites, praziquantel.

•Half-lives: hours (metronidazole) to weeks (chloroquine, mefloquine).

4.5 Pharmacodynamics

• Time-dependent killing vs concentration-dependent killing (metronidazole vs artemisinin).

• Combination therapy takes advantage of synergy (e.g., ACT against malaria).

5. Adverse Effects

Drug Class	Common Effects	Serious/Toxic Effects
Antimalarials	GI upset, dizziness	Chloroquine → retinopathy; Quinine → cinchonism; Mefloquine → neuropsychiatric effects
Antiprotozoals	Nausea, metallic taste	Metronidazole → peripheral neuropathy, disulfiram reaction; Nitazoxanide → mild hepatotoxicity
Antihelminthics	Abdominal discomfort, headache	Albendazole → hepatotoxicity, bone marrow suppression; Ivermectin → CNS toxicity at high doses
Ectoparasiticides	Local irritation	Lindane → neurotoxicity with overuse

6. Drug Interactions

6.1 Pharmacokinetic Interactions

•**CYP450 induction:** rifampicin, phenytoin reduce albendazole, chloroquine, mefloquine levels.

•**CYP450 inhibition:** ketoconazole, cimetidine increase toxicity risk.

•**Absorption interference:** antacids reduce chloroquine; grapefruit juice increases mefloquine bioavailability.

•**Protein binding displacement:** warfarin, digoxin.

6.2 Pharmacodynamic Interactions

•**Additive QT prolongation:** chloroquine + macrolides.

•**CNS depression:** ivermectin + sedatives.

•**Disulfiram-like reaction:** metronidazole + alcohol.

•**Hepatotoxicity:** albendazole + isoniazid.

•**Synergistic combinations:** artemisinin + lumefantrine.

7. Special Considerations

•**Pregnancy:** safe – pyrantel, mebendazole (2nd/3rd trimester); avoid primaquine, albendazole.

•**Liver/Renal Impairment:** albendazole, metronidazole, quinine dose reduction.

•**G6PD Deficiency:** avoid primaquine; risk of haemolysis.

•**Children:** weight-based dosing; avoid neurotoxic drugs (lindane).

•**Combination Therapy:** ACT, DEC + albendazole for filariasis.

8. Resistance Mechanisms

•**Genetic mutations:** e.g., Pfcrt (chloroquine), DHFR/DHPS (antifolate).

•**Efflux pumps:** P-glycoprotein reduces intracellular drug levels.

•**Drug activation reduction:** decreased nitro reductase → metronidazole resistance.

•**Target modification:** altered β-tubulin → benzimidazole resistance.

8.1 Global Patterns

•**Southeast Asia:** high chloroquine resistance.

•**Sub-Saharan Africa:** ACT partially effective; mefloquine resistance emerging.

•**Soil-transmitted helminths:** benzimidazole resistance in livestock; human cases increasing.

9. Future Directions

•**New targets:** parasite kinases, metabolic enzymes, transporters.

•**Nanotechnology:** liposomal formulations, delivery to liver or CNS.

•**Pharmacogenomics:** host CYP polymorphisms on drug metabolism.

•**Vaccines:** RTS,S malaria vaccine; helminth and protozoal vaccine research.

•**Combination therapy:** dual- and triple-drug regimens to limit resistance emergence.

10. Case Illustrations

10.1 Metronidazole-Alcohol Reaction

•45-year-old patient treated for Giardia lamblia develops flushing, nausea, tachycardia after alcohol intake.

•Mechanism: inhibition of aldehyde dehydrogenase → acetaldehyde accumulation.

•Management: abstain from alcohol; symptomatic treatment.

10.2 Chloroquine-QT Prolongation

• 30-year-old traveler on chloroquine prophylaxis against malaria experiences palpitations when taking concomitant erythromycin.

• Mechanism: additive effect on cardiac potassium channels → QT prolongation.

• Management: ECG monitoring; switch to alternative antimalarial.

11. Molecular Pharmacology of Major Antiparasitic Classes

11.1 Antimalarials

Antimalarial medications act on specific stages of the Plasmodium life cycle—either on the hepatic schizont (exoerythrocytic stage) or on the erythrocytic schizont (blood stage).

1. 4-Aminoquinolines (e.g., chloroquine, hydroxychloroquine):

• Mechanism: Chloroquine is sequestered in the acidic food vacuole of Plasmodium parasites, where it inhibits toxic heme (ferriprotoporphyrin IX) polymerization into hemozoin. The accumulation of free heme kills the parasite membranes and causes death.

• Resistance: Mutation in the Pfcrt (chloroquine resistance transporter) gene reduces drug sequestration within the vacuole.

2. Artemisinin and artemisinin derivatives (artemether, artesunate):

• Mechanism: Artemisinin endoperoxide bridge reacts with ferrous iron to form free radicals that alkylate parasite proteins.

•Resistance: Kelch13 gene mutations reduce artemisinin activation.

3. Antifolates (pyrimethamine, proguanil):

•Mechanism: Inhibit dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), blocking folate synthesis needed for DNA replication.

•Resistance: DHFR and DHPS point mutations.

4. Quinoline-methanols (mefloquine, quinine):

•Mechanism: Disrupt heme polymerization similar to chloroquine but at other sites.

•Adverse effects: Tinnitus, dizziness ("cinchonism"), psychosis.

5. Atovaquone-proguanil (Malarone):

•Mechanism: Atovaquone blocks mitochondrial cytochrome bc1 complex → loss of membrane potential → inhibition of pyrimidine synthesis.

•Resistance: Mutation in cytochrome b gene.

11.2 Antiprotozoals

1. Nitroimidazoles (metronidazole, tinidazole):

•Mechanism: Reduced under anaerobic conditions to cytotoxic radicals, damaging DNA and proteins.

•Pharmacokinetics: Oral absorption complete, hepatic metabolism through CYP2A6 and CYP3A4.

•Toxicity: Peripheral neuropathy, metallic taste, and disulfiram-like reaction with ethanol.

2. Pentavalent antimonials (sodium stibogluconate, meglumine antimoniate):

•Mechanism: Block parasite glycolysis and fatty acid oxidation in Leishmania.

•Toxicity: Cardiotoxicity, pancreatitis, hepatotoxicity.

3. Nitazoxanide:

•Mechanism: Blocks pyruvate:ferredoxin oxidoreductase-dependent electron transfer.

• Effective against Giardia lamblia and Cryptosporidium parvum.

11.3 Antihelminthic Agents

1. Benzimidazoles (albendazole, mebendazole):

• Mechanism: Bind β-tubulin → inhibit microtubule polymerization → impaired glucose uptake → ATP depletion → death.

• Resistance: Mutation in β-tubulin gene at codon 200 or 167.

2. Macrocyclic lactones (ivermectin):

• Mechanism: Potentiates glutamate-gated chloride channels → hyperpolarization → paralysis.• Resistance: Overexpression of P-glycoprotein efflux pumps.

3. Praziquantel:

• Mechanism: Increases calcium influx in trematodes/cestodes → spastic paralysis and tegumental damage.

• Toxicity: Headache, dizziness, abdominal discomfort.

4. Pyrantel pamoate:

• Mechanism: depolarizing neuromuscular blocker causing paralysis of worms.

11.4 Ectoparasiticides

• **Permethrin:** targets insect voltage-gated sodium channels → sustained depolarization → paralysis.

• **Lindane (γ-HCH):** inhibits GABA-gated chloride channels → risk of neurotoxicity.

• **Ivermectin (topical/oral):** enhancement of chloride conductance via glutamate-gated channels.

12. Toxicological Aspects

12.1 Acute Toxicity

• Chloroquine: toxic on overdose (cardiac arrest, arrhythmia).

• Antimonials: severe hepatotoxicity and nephrotoxicity.

• Ivermectin: at high doses → activation of GABA receptors → coma, hypotension.

• Metronidazole: encephalopathy and seizures (uncommon).

12.2 Chronic Toxicity

• Chronic administration of chloroquine → retinopathy due to storage in retinal pigment epithelium.

• Albendazole → reversible alopecia, leukopenia with prolonged therapy.

• Nitroimidazoles → peripheral neuropathy.

12.3 Management of Toxicity

• Supportive treatment, activated charcoal in acute overdose.

• In chloroquine toxicity → diazepam and mechanical ventilation.

• In antimonial toxicity → withdrawal + hydration + corticosteroids if myocarditis occurs.

13. Pharmacogenomics and Clinical Variability

• CYP2C19 polymorphism affects proguanil activation.

• CYP3A4/5 variants influence albendazole sulfoxide metabolism.

• G6PD deficiency → primaquine, tafenoquine-induced hemolysis.

• ABCB1 polymorphisms alter ivermectin efflux → CNS effects.

• UGT1A1 and GST polymorphisms may modify nitazoxanide metabolism.

Clinical implication: individualized dosing and screening (e.g., G6PD screening before primaquine).

14. Expanded Section: Drug Interactions

14.1 Pharmacokinetic Interactions

Mechanism	Example	Effect
Enzyme induction	Rifampicin ↓ albendazole/metronidazole levels	Therapeutic failure
Enzyme inhibition	Cimetidine ↑ chloroquine toxicity	QT prolongation
P-glycoprotein inhibition	Verapamil + ivermectin	Neurotoxicity risk
Reduced absorption	Antacids + chloroquine	Reduced bioavailability
Protein binding displacement	Warfarin + albendazole	Bleeding risk

14.2 Pharmacodynamic Interactions

• Additive neurotoxicity: ivermectin + benzodiazepines.

• Additive hepatotoxicity: albendazole + isoniazid or rifampicin.

• QT prolongation: mefloquine + fluoroquinolones or macrolides.

• Antagonism: chloroquine suppresses metronidazole activity by pH alteration in vacuoles.

• Synergism: ACT (artemether-lumefantrine) increases cure rate and reduces resistance

15. Public and Global Health Considerations

• WHO promotes combined mass drug administration (MDA) with albendazole, praziquantel, and ivermectin for neglected tropical diseases (NTDs).

• Control of malaria: ACTs as first-line therapy, intermittent preventive treatment (IPTp) in pregnant women, and seasonal chemoprophylaxis in endemic areas.

• Schistosomiasis: distribution campaigns of praziquantel.

•Onchocerciasis: ivermectin-based MDA by the African Programme for Onchocerciasis Control (APOC).

•Resistance monitoring: molecular surveillance (K13 mutations, DHFR/DHPS genotyping).

16. Progress in Drug Development

•**Diverse scaffolds:** spiroindolones (cipargamin) and ozonides (OZ439).

•**Repurposing:** antibiotics like doxycycline against Wolbachia in filarial worms.

•**Nanoparticle formulations:** improved solubility and tissue targeting for albendazole.

•**Immunopharmacology:** vaccine adjuvants combined with antiparasitic chemotherapy for synergistic protection.

17. Conclusion

The clinical pharmacology of antiparasitic drugs exhibits varied mechanisms of action against protozoa, helminths, and ectoparasites. A clear comprehension of molecular mechanisms, host genetics, and pharmacokinetic–pharmacodynamic relationships is essential to optimize therapy and prevent resistance.

Emergence of drug-resistant strains, coupled with international travel and global warming, necessitates continued pharmacovigilance and innovation. The integration of genomic screening, rational combination therapy, and community-based interventions remains the cornerstone of sustainable control of parasitic diseases.

18. References

1. Brunton LL, Hilal-Dandan R, Kollmann BC. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 14th edition. McGraw-Hill, 2020.

2. Croft SL, Olliaro P. Leishmaniasis chemotherapy—challenges and opportunities. Clin Microbiol Infect. 2011;17(10):1478–1483.

3. White NJ. Antimalarial drug resistance. J Clin Invest. 2004;113(8):1084–1092.

4. Walker K, Hall K. Pharmacology and drug interactions of antiparasitic agents. Expert Rev Clin Pharmacal. 2019;12(8):745–758.

5. Hill DR, et al. CDC Health Information for International Travel 2024. Oxford University Press, 2024.

6. Hotez PJ, et al. Helminth infections: the great neglected tropical diseases. J Clin Invest. 2008;118(4):1311–1321.

7. Ashley EA, et al. Artemisinin resistance in Plasmodium falciparum. N Engl J Med. 2014;371:411–423.

8. Keiser J, Utzinger J. Anthelminthic drugs for soil-transmitted helminthiasis. Expert Opin Pharmacother. 2008;9:1071–1080.